156 related articles for article (PubMed ID: 30955405)
21. Potentially inappropriate anticholinergic medication use in community-dwelling older adults: a national cross-sectional study.
Kachru N; Carnahan RM; Johnson ML; Aparasu RR
Drugs Aging; 2015 May; 32(5):379-89. PubMed ID: 25832970
[TBL] [Abstract][Full Text] [Related]
22. Potentially Inappropriate Prescribing for Prostatic Hyperplasia in Older Persons.
Renoncourt T; Saint F; Bennis Y; Mondet L; Bloch F
J Am Med Dir Assoc; 2022 Jun; 23(6):992-997. PubMed ID: 34653381
[TBL] [Abstract][Full Text] [Related]
23. Use of anticholinergic drugs in older patients.
Reiter L; Stenberg-Nilsen H; Økland HG
Tidsskr Nor Laegeforen; 2021 Apr; 141(6):. PubMed ID: 33876622
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis.
Filson CP; Hollingsworth JM; Clemens JQ; Wei JT
J Urol; 2013 Dec; 190(6):2153-60. PubMed ID: 23727412
[TBL] [Abstract][Full Text] [Related]
25. Inhaled anticholinergic drugs and risk of acute urinary retention.
Afonso AS; Verhamme KM; Stricker BH; Sturkenboom MC; Brusselle GG
BJU Int; 2011 Apr; 107(8):1265-72. PubMed ID: 20880196
[TBL] [Abstract][Full Text] [Related]
26. Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project.
Welliver C; Feinstein L; Ward JB; Fwu CW; Kirkali Z; Bavendam T; Matlaga BR; McVary KT;
J Urol; 2020 Jan; 203(1):171-178. PubMed ID: 31430232
[TBL] [Abstract][Full Text] [Related]
27. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
[TBL] [Abstract][Full Text] [Related]
28. Potentially inappropriate anticholinergic medication use in older adults with dementia.
Kachru N; Carnahan RM; Johnson ML; Aparasu RR
J Am Pharm Assoc (2003); 2015; 55(6):603-612. PubMed ID: 26501745
[TBL] [Abstract][Full Text] [Related]
29. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia: A randomized clinical trial.
Baghani Aval H; Ameli Z; Ameli M
Urologia; 2018 May; 85(2):51-54. PubMed ID: 30043714
[TBL] [Abstract][Full Text] [Related]
31. Temporal trends in anticholinergic medication prescription in older people: repeated cross-sectional analysis of population prescribing data.
Sumukadas D; McMurdo ME; Mangoni AA; Guthrie B
Age Ageing; 2014 Jul; 43(4):515-21. PubMed ID: 24334709
[TBL] [Abstract][Full Text] [Related]
32. Safety of anticholinergics in patients with benign prostatic hyperplasia.
Athanasopoulos A; Mitropoulos D; Giannitsas K; Perimenis P
Expert Opin Drug Saf; 2008 Jul; 7(4):473-9. PubMed ID: 18613810
[TBL] [Abstract][Full Text] [Related]
33. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study.
Lu WH; Wen YW; Chen LK; Hsiao FY
CMAJ; 2015 Mar; 187(4):E130-E137. PubMed ID: 25646290
[TBL] [Abstract][Full Text] [Related]
34. Drug Prescription Patterns During Initial Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Study Based on Health Insurance Review and Assessment Database.
Lee JW; Kim JH
J Korean Med Sci; 2022 Mar; 37(12):e95. PubMed ID: 35347903
[TBL] [Abstract][Full Text] [Related]
35. [Benign prostatic hypertrophy, bladder hyperactivity and anticholinergic].
Grisard S; Long JA
Rev Prat; 2018 Apr; 68(4):e148. PubMed ID: 30869402
[No Abstract] [Full Text] [Related]
36. α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database.
Tae BS; Jeon BJ; Choi H; Cheon J; Park JY; Bae JH
J Urol; 2019 Aug; 202(2):362-368. PubMed ID: 30840545
[TBL] [Abstract][Full Text] [Related]
37. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia.
Nichol MB; Knight TK; Wu J; Barron R; Penson DF
J Urol; 2009 May; 181(5):2214-21; discussion 2221-2. PubMed ID: 19296986
[TBL] [Abstract][Full Text] [Related]
38. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
[TBL] [Abstract][Full Text] [Related]
39. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
40. Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics.
Cross AJ; George J; Woodward MC; Ames D; Brodaty H; Wolfe R; Connors MH; Elliott RA
J Alzheimers Dis; 2017; 60(2):349-358. PubMed ID: 28869467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
